Literature DB >> 29059436

Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer.

Peter B Bach1, Leonard B Saltz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29059436     DOI： 10.1093/jnci/djx125

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents.

Authors:  Charles W Given; Barbara A Given; Alla Sikorskii; John C Krauss; Eric Vachon
Journal:  Support Care Cancer       Date:  2018-08-23       Impact factor: 3.603

Review 2.  Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?

Authors:  Alex Renner; Mauricio Burotto; Carlos Rojas
Journal:  J Glob Oncol       Date:  2019-07

3.  Is flat dosing cost-effective? Re: 'The same old story': thoughts on authorised doses of anticancer drugs.

Authors:  Abdul R Farooq; Timothy O'Brien; Seamus O'Reilly
Journal:  Ther Adv Med Oncol       Date:  2020-12-25       Impact factor: 8.168

4.  Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer.

Authors:  Jia Li Low; Yiqing Huang; Kenneth Sooi; Yvonne Ang; Zhi Yao Chan; Katie Spencer; Anand Devaprasath Jeyasekharan; Raghav Sundar; Boon Cher Goh; Ross Soo; Wei Peng Yong
Journal:  Int J Cancer       Date:  2021-03-06       Impact factor: 7.316
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.